deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03070327

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Conditions Multiple Myeloma
Interventions Cyclophosphamide EGFRt/BCMA-41BBz CAR T cell Lenalidomide.
Updated 20 times since 2017 Last updated: Mar 2, 2026 Started: Feb 27, 2017 Primary completion: Feb 28, 2027 Completion: Feb 28, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Multiple Myeloma, this trial is ongoing. The trial is conducted by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and has accumulated 20 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Dec 2020 · 11 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Mar 2026 · 10 months · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

20 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. May 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 15 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Apr 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  10. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  11. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  13. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  15. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations